top of page

IO Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year

Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and IDO, and which has breakthrough therapy designation. A pivotal study in first line metastatic melanoma will read out soon.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page